Dr. David Dix is a Clinical Associate Professor and has been a faculty member in the Division of Pediatric Hematology/Oncology (PHO) at BCCH since October 2001. Education has been a primary focus of his academic career. His involvement has spanned undergraduate and post-graduate training, and his contributions have been on departmental, provincial and national levels. Dr. Dix’s research efforts include conducting and participating in clinical trials and quality of life (QoL) studies within the field of pediatric oncology. Since 2007 he has served as chair of the Children’s Oncology Group (COG) Phase III Study AREN0533: “Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors”. It is likely that the results of this international study will change the way in which children with Higher Risk Favorable Histology Wilms Tumors are treated world-wide. In 2012, Dr Dix was appointed a Coordinating Principle Investigator for the Langerhans Cell Histiocytosis (LCH) IV study, an international study for the treatment of pediatric patients and young adults with LCH. In addition, his research has focused on supportive care issues in the field of PHO, as well as quality of life research examining the psycho-social impact of childhood cancer. Within this field Dr Dix has successfully collaborated and published with a number of Canadian and International research groups. While Dr. Dix has a substantial interest in and commitment to education and research, the major focus of his daily work and of his career remains the clinical care that he provides to patients within the Division of Pediatric Hematology/Oncology.